|
| 37493197 | ALSUntangled #71: Nuedexta. | Amyotroph Lateral Scler Frontotemporal Degener | 2024 |
| 38018119 | ALSUntangled #72: Insulin. | Amyotroph Lateral Scler Frontotemporal Degener | 2024 |
| 34645313 | ALSUntangled #63: ketogenic diets. | Amyotroph Lateral Scler Frontotemporal Degener | 2023 |
| 35775279 | Study of "ALS reversals": LifeTime environmental exposures (StARLiTE). | Amyotroph Lateral Scler Frontotemporal Degener | 2023 |
| 37394036 | Intercellular transmission of pathogenic proteins in ALS: Exploring the pathogenic wave. | Neurobiol Dis | 2023 |
| 37219865 | Clenbuterol Treatment Is Safe and Associated With Slowed Disease Progression in a Small Open-Label Trial in Patients With Amyotrophic Lateral Sclerosis. | J Clin Neuromuscul Dis | 2023 |
| 37190795 | The amyotrophic lateral sclerosis-health index (ALS-HI): development and evaluation of a novel outcome measure. | Amyotroph Lateral Scler Frontotemporal Degener | 2023 |
| 37288776 | ALSUntangled #70: caffeine. | Amyotroph Lateral Scler Frontotemporal Degener | 2023 |
| 36694292 | ALSUntangled # 69: astaxanthin. | Amyotroph Lateral Scler Frontotemporal Degener | 2023 |
| 36398749 | ALSUntangled #68: ozone therapy. | Amyotroph Lateral Scler Frontotemporal Degener | 2023 |
| 36705941 | An evaluation of the combination of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. | Expert Rev Neurother | 2023 |
| 36106861 | ALSUntangled #67: rituximab. | Amyotroph Lateral Scler Frontotemporal Degener | 2023 |
| 35997522 | ALSUntangled #65: glucocorticoid corticosteroids. | Amyotroph Lateral Scler Frontotemporal Degener | 2023 |
| 35913017 | ALSUntangled #66: antimycobacterial antibiotics. | Amyotroph Lateral Scler Frontotemporal Degener | 2023 |
| 34187257 | ALSUntangled #62: vitamin C. | Amyotroph Lateral Scler Frontotemporal Degener | 2022 |
| 36712738 | Filtered Cerebrospinal Fluid From Patients With Amyotrophic Lateral Sclerosis Displays an Altered Proteome and Affects Motor Phenotype in a Mouse Model. | Cureus | 2022 |
| 36531982 | Patient reported impact of symptoms in amyotrophic lateral sclerosis (PRISM-ALS): A national, cross-sectional study. | EClinicalMedicine | 2022 |
| 36251310 | Amyotrophic Lateral Sclerosis Clinical Trials and Interpretation of Functional End Points and Fluid Biomarkers: A Review. | JAMA Neurol | 2022 |
| 36042248 | Intronic NEFH variant is associated with reduced risk for sporadic ALS and later age of disease onset. | Sci Rep | 2022 |
| 33683159 | ALSUntangled #60: light therapy. | Amyotroph Lateral Scler Frontotemporal Degener | 2022 |
| 35225121 | ALSUntangled #64: butyrates. | Amyotroph Lateral Scler Frontotemporal Degener | 2022 |
| 32672072 | Total serum immunoglobulin A in ALS. | Amyotroph Lateral Scler Frontotemporal Degener | 2021 |
| 33841129 | Novel <i><i>STMN2</i></i> Variant Linked to Amyotrophic Lateral Sclerosis Risk and Clinical Phenotype. | Front Aging Neurosci | 2021 |
| 34878988 | Recruitment of Patients With Amyotrophic Lateral Sclerosis for Clinical Trials and Epidemiological Studies: Descriptive Study of the National ALS Registry's Research Notification Mechanism. | J Med Internet Res | 2021 |
| 34816762 | MN-166 (ibudilast) in amyotrophic lateral sclerosis in a Phase IIb/III study: COMBAT-ALS study design. | Neurodegener Dis Manag | 2021 |
| 34131925 | COVID-19-accelerated disease progression in two patients with amyotrophic lateral sclerosis. | Muscle Nerve | 2021 |
| 33993457 | Pathophysiology and Treatment of Non-motor Dysfunction in Amyotrophic Lateral Sclerosis. | CNS Drugs | 2021 |
| 34255865 | Infection rate, mortality and characteristics of veterans with amyotrophic lateral sclerosis with COVID-19. | Muscle Nerve | 2021 |
| 33226425 | Effect of Ezogabine on Cortical and Spinal Motor Neuron Excitability in Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial. | JAMA Neurol | 2021 |
| 33474997 | ALSUntangled 59: Tamoxifen. | Amyotroph Lateral Scler Frontotemporal Degener | 2021 |
| 33327734 | Continuing Non-Invasive Ventilation During Amyotrophic Lateral Sclerosis-Related Hospice Care Is Medically, Administratively, and Financially Feasible. | Am J Hosp Palliat Care | 2021 |
| 32838576 | Engaging ALS patients and caregivers (the ALS research ambassadors) to help design the REFINE-ALS biomarker study. | Amyotroph Lateral Scler Frontotemporal Degener | 2021 |
| 32396393 | Understanding the needs of people with ALS: a national survey of patients and caregivers. | Amyotroph Lateral Scler Frontotemporal Degener | 2020 |
| 31886839 | Development and Validation of the Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS). | JAMA Neurol | 2020 |
| 33077544 | Identification of a pathogenic intronic KIF5A mutation in an ALS-FTD kindred. | Neurology | 2020 |
| 32754644 | Disease-modifying effects of an <i>SCAF4</i> structural variant in a predominantly <i>SOD1</i> ALS cohort. | Neurol Genet | 2020 |
| 32445195 | Amyotrophic lateral sclerosis care and research in the United States during the COVID-19 pandemic: Challenges and opportunities. | Muscle Nerve | 2020 |
| 32276554 | Plasma creatinine and oxidative stress biomarkers in amyotrophic lateral sclerosis. | Amyotroph Lateral Scler Frontotemporal Degener | 2020 |
| 32458763 | ALS clinical research learning institutes (ALS-CRLI): empowering people with ALS to be research ambassadors. | Amyotroph Lateral Scler Frontotemporal Degener | 2020 |
| 30430873 | ALSUntangled 46: penicillin G/hydrocortisone. | Amyotroph Lateral Scler Frontotemporal Degener | 2019 |
| 31719072 | Study protocol for a randomised, double-blind, placebo-controlled study evaluating the Efficacy of cannabis-based Medicine Extract in slowing the disease pRogression of Amyotrophic Lateral sclerosis or motor neurone Disease: the EMERALD trial. | BMJ Open | 2019 |
| 31885727 | Corrigendum to "Longitudinal Screening Detects Cognitive Stability and Behavioral Deterioration in ALS Patients". | Behav Neurol | 2019 |
| 30786786 | ALSUntangled 48: Perampanel (Fycompa). | Amyotroph Lateral Scler Frontotemporal Degener | 2019 |
| 30689428 | ALSUntangled No. 47: RT001. | Amyotroph Lateral Scler Frontotemporal Degener | 2019 |
| 30663902 | Lunasin does not slow ALS progression: results of an open-label, single-center, hybrid-virtual 12-month trial. | Amyotroph Lateral Scler Frontotemporal Degener | 2019 |
| 28920459 | ALSUntangled 42: Elysium health's "basis". | Amyotroph Lateral Scler Frontotemporal Degener | 2018 |
| 29950436 | Independent home use of a brain-computer interface by people with amyotrophic lateral sclerosis. | Neurology | 2018 |
| 29607695 | "ALS reversals": demographics, disease characteristics, treatments, and co-morbidities. | Amyotroph Lateral Scler Frontotemporal Degener | 2018 |
| 29493344 | ALSUntangled 44: curcumin. | Amyotroph Lateral Scler Frontotemporal Degener | 2018 |
| 29193151 | Refractory myasthenia gravis exacerbation triggered By pembrolizumab. | Muscle Nerve | 2018 |